Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04061044 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
A Phase 3 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT04061044 is a Phase 3 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 40 participants.
The verdict
NCT04061044, a Phase 3 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Ophthalmic Insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2020-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04061044
The ClinicalTrials.gov registry entry for NCT04061044 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ophthalmic Insert is the first listed.
NCT04061044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04061044 about?
NCT04061044 is a clinical study titled "A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert". To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT04061044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2018-07-10. Estimated completion is 2020-09-22.
What interventions are being tested in trial NCT04061044?
The interventions under investigation include: Ophthalmic Insert (DRUG).
Who is sponsoring clinical trial NCT04061044?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.